AlphAIAlphAI — Financial news for AI agents
finanznachrichten.deNOV 32 min read$CLVT

Clarivate Plc: Clarivate Reports Third Quarter 2026 Results, Delivering Clear Path to Value Creation

Clarivate Plc (CLVT) reported Q3 2026 results, with total revenues of $567.9M, including the divested Life Sciences & Healthcare segment. Organic recurring revenue grew 0.4%, and adjusted net income was $136.0M. The company updated its 2026 outlook, focusing on sustained growth and cash flow.

Original reporting
finanznachrichten.de
Published Nov 3, 2026, 11:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 12:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$CLVT
Bearish
high confidence
Mentioned
$CLVT
Relevance
8/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$CLVTBearishMed
01

Why it matters

The earnings release highlights a transition period with short‑term losses but potential long‑term upside from a streamlined portfolio.

02

Market read

First‑time earnings disclosure with significant loss and divestiture details provides fresh data for traders.

03

What to watch

Cash from the LS&H sale ($488.4M) improves balance sheet strength and may support future buybacks.

Relevance 8/10Novelty 8/10Timing: today

Background

Clarivate is a global provider of transformative intelligence, recently completing the sale of its Life Sciences & Healthcare segment.

Company-level read

Ticker impact

$CLVTBearishHigh confidence
Context

Clarivate reported Q3 2026 results with a net loss of $80.8M and a $62.2M goodwill impairment after divesting its Life Sciences & Healthcare segment.

Expected impact

likely downward pressure as investors digest the loss and impairment charge

Evidence & confidence

The disclosed loss and impairment are new material information that can prompt sell‑offs.

Market effects

Sector

The divestiture may sharpen focus on Clarivate's core IP and academia segments, affecting peers in the information services sector.

Regional

Limited to U.S. and European markets where Clarivate's customers operate.

Global

Modest, as the company is a niche data provider.

Counterpoint

What could challenge this read

The impairment could be a one‑time hit, and the refocused business may drive future growth, offering a buying opportunity.

Key entities

  • Executive
    Matti Shem Tov

    Chief Executive Officer of Clarivate

  • Executive
    Michael Easton

    Chief Financial Officer of Clarivate

Read at source← All news

StoryClarivate reports Q3 loss as continuing revenue falls after LS&H divestiture

Also covered by

4 outlets

Related articles

NOV 3
$CLVTHighAI 8/10

Clarivate Reports Third Quarter 2026 Results, Delivering Clear Path to Value Creation

CLARIVATE PLC (CLVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. 1 Clarivate Reports Third Quarter 2026 Results, Delivering Clear Path to Value Creation — Improved recurring organic revenue growth driven by portfolio transformation and AI-led innovation — — Updates 2026 financial outlook following the divestiture of Life Sciences & Healthcare

SEC EDGAR 8-K3 min
NOV 3
$CLVTMed

Why is Clarivate stock sliding today?

Clarivate (CLVT) stock fell 5.4% in pre-market trading after Q3 2026 results beat EPS estimates ($0.21 vs. $0.18) but missed revenue forecasts by 16.7% ($481.6M vs. $566.77M), down 9.2% YoY. Full-year revenue guidance ($1.96B-$1.98B) also fell short of consensus ($2.20B). The miss was exacerbated by portfolio disposals and cautious forward outlook.

investing.com2 min
NOV 3
$CLVTHighAI 8/10

Clarivate shares fall 6% on revenue miss despite earnings beat

Clarivate (CLVT) reported Q3 earnings of $0.21 per share, beating estimates, but revenue of $481.6M missed expectations. Shares fell 6.63% premarket. Q4 guidance was mixed, with EPS matching estimates but revenue below. The company expects fiscal 2026 revenue of $1.97B, below consensus. Organic revenue grew 0.4% YoY, and adjusted EBITDA declined 1.8%.

investing.com2 min